

Alon Harris, MS, PhD, FARVO

Vice Chair of International Research and Academic Affairs
Director of Ophthalmic Vascular Diagnostic
& Research Program at Mount Sinai Hospital
Professor of Ophthalmology
Icahn School of Medicine at Mount Sinai
Department of Ophthalmology
New York, NY



Professor Alon Harris is a world expert and leader in the field of ocular blood flow. He is an internationally recognized clinical researcher focusing on glaucoma risk factor assessment, monitoring techniques for structural and functional glaucoma progression, ocular perfusion assessment, glaucoma medications, generic medications, imaging methodologies, population-based studies, and artificial intelligence and mathematical modeling approaches in ophthalmology.

Professor Harris founded and established one of the world's leading centers for ocular blood flow and its implications to glaucoma, diabetic retinopathy, age-related macular degeneration and non-arteritic ischemic optic neuropathy at the Indiana University School of Medicine. He has published over 380 peer-reviewed journal articles, 23 books and 69 book chapters. Dr. Harris is the Co-founder and Chief Editor for the *Journal Modeling and Artificial Intelligence in Ophthalmology* (MAIO).

Professor Harris has received numerous national and international awards including the Sam Rothberg Glaucoma Award; the William and Mary Greve International Research Scholar Award from the Research to Prevent Blindness organization; the Glenn W. Irwin Jr., MD., Experience Excellence Recognition Award; Edmund Benjamin Spaeth Oration Award for Outstanding Clinical Research; American Academy of Ophthalmology Achievement Award and Letzter Endowed Chair of Ophthalmology

Professor Harris has received over 6 million dollars in research funds from prestigious institutions including the National Institutes of Health, National Science Foundation, American Diabetes Association, and the National Eye Institute in the United States.

Professor Harris has extensive experience transitioning academic discovery to marketplace solutions and currently serves as Chairman of the Board for XLVision and SlitLed, and as consultant to many small biotech companies. Dr. Harris is also the founder of AdOM, a novel ophthalmic medical imaging company developing modalities for assessment of dry eye disease and has previously served as a senior consultant to major pharmaceutical companies including Merck, Pfizer, Alcon, and Allergan.

Professor Harris holds two patents related to ocular blood flow: 1) Novel Treatment of Macular Edema; and 2) Method to Increase Retinal and Optic Nerve Head Blood Flow.